Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 116

1.

Isavuconazole: Case Report and Pharmacokinetic Considerations.

Marchesi F, Girmenia C, Goffredo BM, Salvatorelli E, Romano A, Mengarelli A, Minotti G, Menna P.

Chemotherapy. 2018 Nov 20;63(5):253-256. doi: 10.1159/000494329. [Epub ahead of print]

PMID:
30458443
2.

The Endogenous Lusitropic and Chronotropic Agent, B-Type Natriuretic Peptide, Limits Cardiac Troponin Release in Cancer Patients with an Early Impairment of Myocardial Relaxation Induced by Anthracyclines.

Menna P, Salvatorelli E, Armento G, Annibali O, Greco C, Marchesi F, Calabrese V, Reggiardo G, Minotti G.

J Pharmacol Exp Ther. 2018 Dec;367(3):518-527. doi: 10.1124/jpet.118.253104. Epub 2018 Oct 1.

PMID:
30275150
3.

Pixantrone: novel mode of action and clinical readouts.

Minotti G, Han H, Cattan V, Egorov A, Bertoni F.

Expert Rev Hematol. 2018 Jul;11(7):587-596. doi: 10.1080/17474086.2018.1476848. Epub 2018 Jun 18.

PMID:
29912583
4.

Intolerance to tyrosine kinase inhibitors in chronic myeloid leukemia: the possible role of ponatinib.

Breccia M, Efficace F, Iurlo A, Luciano L, Abruzzese E, Gozzini A, Pregno P, Tiribelli M, Rosti G, Minotti G.

Expert Opin Drug Saf. 2018 Jun;17(6):623-628. doi: 10.1080/14740338.2018.1480719. Epub 2018 May 30. Review.

PMID:
29845876
5.

The International Cardioncology Society-ONE trial: Not all that glitters is for cardioncologists only.

Minotti G.

Eur J Cancer. 2018 Jul;97:27-29. doi: 10.1016/j.ejca.2018.04.003. Epub 2018 May 3. No abstract available.

PMID:
29731230
6.

Pharmacology of Cardio-Oncology: Chronotropic and Lusitropic Effects of B-Type Natriuretic Peptide in Cancer Patients with Early Diastolic Dysfunction Induced by Anthracycline or Nonanthracycline Chemotherapy.

Menna P, Calabrese V, Armento G, Annibali O, Greco C, Salvatorelli E, Marchesi F, Reggiardo G, Minotti G.

J Pharmacol Exp Ther. 2018 Jul;366(1):158-168. doi: 10.1124/jpet.118.249235. Epub 2018 May 2.

PMID:
29720563
7.

Practical management of ibrutinib in the real life: Focus on atrial fibrillation and bleeding.

Boriani G, Corradini P, Cuneo A, Falanga A, Foà R, Gaidano G, Ghia PP, Martelli M, Marasca R, Massaia M, Mauro FR, Minotti G, Molica S, Montillo M, Pinto A, Tedeschi A, Vitolo U, Zinzani PL.

Hematol Oncol. 2018 Oct;36(4):624-632. doi: 10.1002/hon.2503. Epub 2018 Mar 7. Review.

PMID:
29512173
8.

Editorial: The Journal Chemotherapy Is for Cardio-Oncologists Too.

Minotti G.

Chemotherapy. 2018 Feb 9;63(2):53-54. doi: 10.1159/000487055. [Epub ahead of print] No abstract available.

PMID:
29428941
9.

Early Diastolic Dysfunction after Cancer Chemotherapy: Primary Endpoint Results of a Multicenter Cardio-Oncology Study.

Calabrese V, Menna P, Annibali O, Armento G, Carpino A, Cerchiara E, Greco C, Marchesi F, Spallarossa P, Toglia G, Reggiardo G, Minotti G; Collaborators.

Chemotherapy. 2018;63(2):55-63. doi: 10.1159/000486761. Epub 2018 Feb 9. Erratum in: Chemotherapy. 2018 Apr 10;63(2):64.

PMID:
29428939
10.

Modified Colistin Regimen for Critically Ill Patients with Acute Renal Impairment and Continuous Renal Replacement Therapy.

Menna P, Salvatorelli E, Mattei A, Cappiello D, Minotti G, Carassiti M.

Chemotherapy. 2018;63(1):35-38. doi: 10.1159/000484974. Epub 2017 Dec 22.

11.

Low-Dose Anthracycline and Risk of Heart Failure in a Pharmacokinetic Model of Human Myocardium Exposure: Analog Specificity and Role of Secondary Alcohol Metabolites.

Salvatorelli E, Menna P, Chello M, Covino E, Minotti G.

J Pharmacol Exp Ther. 2018 Feb;364(2):323-331. doi: 10.1124/jpet.117.246140. Epub 2017 Dec 8.

PMID:
29222131
12.

Early diagnosis of acute coronary syndrome.

Katus H, Ziegler A, Ekinci O, Giannitsis E, Stough WG, Achenbach S, Blankenberg S, Brueckmann M, Collinson P, Comaniciu D, Crea F, Dinh W, Ducrocq G, Flachskampf FA, Fox KAA, Friedrich MG, Hebert KA, Himmelmann A, Hlatky M, Lautsch D, Lindahl B, Lindholm D, Mills NL, Minotti G, Möckel M, Omland T, Semjonow V.

Eur Heart J. 2017 Nov 1;38(41):3049-3055. doi: 10.1093/eurheartj/ehx492.

PMID:
29029109
13.

Cancer drugs and QT prolongation: weighing risk against benefit.

Menna P, Salvatorelli E, Minotti G.

Expert Opin Drug Saf. 2017 Oct;16(10):1099-1102. doi: 10.1080/14740338.2017.1354987. Epub 2017 Jul 20. No abstract available.

PMID:
28699784
14.

Modeling Human Myocardium Exposure to Doxorubicin Defines the Risk of Heart Failure from Low-Dose Doxorubicin.

Salvatorelli E, Menna P, Chello M, Covino E, Minotti G.

J Pharmacol Exp Ther. 2017 Aug;362(2):263-270. doi: 10.1124/jpet.117.242388. Epub 2017 May 30.

15.

Do You Know Pixantrone?

Minotti G, Menna P, Salvatorelli E.

Chemotherapy. 2017;62(3):192-193. doi: 10.1159/000464276. Epub 2017 Mar 24. No abstract available.

16.

The Influence of Dietary Components on Early Signs of Atherosclerosis in Apparently Healthy Young-adult Males: An Observational Study of 615 Subjects.

Minotti GC, Cortese F, Corsonello A, Guadalupi G, D Arcangelo AP, Palumbo SD, Naio R, Clemente O, Aurelio A, Carone S, Gelsumino T, Gemignani V, Bianchini E, Vigotti M, Faita F, Greco L, Primerano R, Incalzi RA, Ciccone MM.

Curr Vasc Pharmacol. 2017;15(5):482-490. doi: 10.2174/1570161115666170201111809.

PMID:
28155612
17.

Valsalva maneuver in phlebologic practice.

Ricci S, Moro L, Minotti GC, Incalzi RA, De Maeseneer M.

Phlebology. 2018 Mar;33(2):75-83. doi: 10.1177/0268355516678513. Epub 2017 Jan 12.

PMID:
28081660
18.

Identification, prevention and management of cardiovascular risk in chronic myeloid leukaemia patients candidate to ponatinib: an expert opinion.

Breccia M, Pregno P, Spallarossa P, Arboscello E, Ciceri F, Giorgi M, Grossi A, Mallardo M, Nodari S, Ottolini S, Sala C, Tortorella G, Rosti G, Pane F, Minotti G, Baccarani M.

Ann Hematol. 2017 Apr;96(4):549-558. doi: 10.1007/s00277-016-2820-x. Epub 2016 Sep 30. Review.

PMID:
27686083
19.

Heart Rate reduction by IVabradine for improvement of ENDothELial function in patients with coronary artery disease: the RIVENDEL study.

Mangiacapra F, Colaiori I, Ricottini E, Balducci F, Creta A, Demartini C, Minotti G, Di Sciascio G.

Clin Res Cardiol. 2017 Jan;106(1):69-75. doi: 10.1007/s00392-016-1024-7. Epub 2016 Aug 12.

PMID:
27520989
20.

Rethinking Drugs from Chemistry to Therapeutic Opportunities: Pixantrone beyond Anthracyclines.

Menna P, Salvatorelli E, Minotti G.

Chem Res Toxicol. 2016 Aug 15;29(8):1270-8. doi: 10.1021/acs.chemrestox.6b00190. Epub 2016 Jul 22.

PMID:
27420111
21.

Drug-induced hepatotoxicity in cancer patients - implication for treatment.

Vincenzi B, Armento G, Spalato Ceruso M, Catania G, Leakos M, Santini D, Minotti G, Tonini G.

Expert Opin Drug Saf. 2016 Sep;15(9):1219-38. doi: 10.1080/14740338.2016.1194824. Epub 2016 Jun 14. Review.

PMID:
27232067
22.

Critical concepts, practice recommendations, and research perspectives of pixantrone therapy in non-Hodgkin lymphoma: a SIE, SIES, and GITMO consensus paper.

Zinzani PL, Corradini P, Martelli M, Minotti G, Oliva S, Spina M, Barosi G, Tura S.

Eur J Haematol. 2016 Dec;97(6):554-561. doi: 10.1111/ejh.12768. Epub 2016 Jul 1.

PMID:
27124765
23.

Editorial.

Minotti G, Graziani G, Delogu G.

Chemotherapy. 2016;61(1):1-2. doi: 10.1159/000441664. Epub 2015 Nov 3. No abstract available.

24.

Managing anthracycline-induced cardiotoxicity: beginning with the end in mind.

Salvatorelli E, Menna P, Minotti G.

Future Cardiol. 2015 Jul;11(4):363-6. doi: 10.2217/FCA.15.35. Epub 2015 Aug 4. No abstract available.

PMID:
26239550
25.

The concomitant management of cancer therapy and cardiac therapy.

Salvatorelli E, Menna P, Cantalupo E, Chello M, Covino E, Wolf FI, Minotti G.

Biochim Biophys Acta. 2015 Oct;1848(10 Pt B):2727-37. doi: 10.1016/j.bbamem.2015.01.003. Epub 2015 Jan 14. Review.

26.

Telaprevir raises the plasma/whole blood ribavirin ratio: trying to come full circle on a dangerous relationship.

Menna P, Gallo P, Vespasiani Gentilucci U, Salvatorelli E, Galati G, Minotti G, Picardi A.

J Viral Hepat. 2014 Oct;21(10):e136-7. doi: 10.1111/jvh.12264. Epub 2014 Jun 16. No abstract available.

PMID:
24935352
27.

Report on the international colloquium on cardio-oncology (rome, 12-14 march 2014).

Ewer M, Gianni L, Pane F, Sandri MT, Steiner RK, Wojnowski L, Yeh ET, Carver JR, Lipshultz SE, Minotti G, Armstrong GT, Cardinale D, Colan SD, Darby SC, Force TL, Kremer LC, Lenihan DJ, Sallan SE, Sawyer DB, Suter TM, Swain SM, van Leeuwen FE.

Ecancermedicalscience. 2014 May 29;8:433. doi: 10.3332/ecancer.2014.433. eCollection 2014.

28.

Low level tumor necrosis factor-alpha protects cardiomyocytes against high level tumor necrosis factor-alpha: brief insight into a beneficial paradox.

Cacciapaglia F, Salvatorelli E, Minotti G, Afeltra A, Menna P.

Cardiovasc Toxicol. 2014 Dec;14(4):387-92. doi: 10.1007/s12012-014-9257-z.

PMID:
24798036
29.

Development of a tumor-specific photoactivatable doxorubicin prodrug.

Girotti AW, Minotti G.

Photochem Photobiol. 2013 Sep-Oct;89(5):1009-10. doi: 10.1111/php.12151. Epub 2013 Sep 3.

30.

Pharmacology at work for cardio-oncology: ranolazine to treat early cardiotoxicity induced by antitumor drugs.

Minotti G.

J Pharmacol Exp Ther. 2013 Sep;346(3):343-9. doi: 10.1124/jpet.113.204057. Epub 2013 Jul 1. Review.

31.

The novel anthracenedione, pixantrone, lacks redox activity and inhibits doxorubicinol formation in human myocardium: insight to explain the cardiac safety of pixantrone in doxorubicin-treated patients.

Salvatorelli E, Menna P, Paz OG, Chello M, Covino E, Singer JW, Minotti G.

J Pharmacol Exp Ther. 2013 Feb;344(2):467-78. doi: 10.1124/jpet.112.200568. Epub 2012 Nov 28.

32.

Pharmacokinetics of pegylated liposomal doxorubicin administered by intraoperative hyperthermic intraperitoneal chemotherapy to patients with advanced ovarian cancer and peritoneal carcinomatosis.

Salvatorelli E, De Tursi M, Menna P, Carella C, Massari R, Colasante A, Iacobelli S, Minotti G.

Drug Metab Dispos. 2012 Dec;40(12):2365-73. doi: 10.1124/dmd.112.047480. Epub 2012 Sep 12.

33.

Pharmacokinetic characterization of amrubicin cardiac safety in an ex vivo human myocardial strip model. II. Amrubicin shows metabolic advantages over doxorubicin and epirubicin.

Salvatorelli E, Menna P, Gonzalez Paz O, Surapaneni S, Aukerman SL, Chello M, Covino E, Sung V, Minotti G.

J Pharmacol Exp Ther. 2012 May;341(2):474-83. doi: 10.1124/jpet.111.190264. Epub 2012 Feb 15.

34.

Pharmacokinetic characterization of amrubicin cardiac safety in an ex vivo human myocardial strip model. I. Amrubicin accumulates to a lower level than doxorubicin or epirubicin.

Salvatorelli E, Menna P, Surapaneni S, Aukerman SL, Chello M, Covino E, Sung V, Minotti G.

J Pharmacol Exp Ther. 2012 May;341(2):464-73. doi: 10.1124/jpet.111.190256. Epub 2012 Feb 15.

35.

Clinical activity and cardiac tolerability of non-pegylated liposomal doxorubicin in breast cancer: a synthetic review.

Airoldi M, Amadori D, Barni S, Cinieri S, De Placido S, Di Leo A, Gennari A, Iacobelli S, Ionta MT, Lorusso V, Lotrionte M, Marchetti P, Mattioli R, Minotti G, Pronzato P, Rosti G, Tondini CA, Veronesi A.

Tumori. 2011 Nov-Dec;97(6):690-2. doi: 10.1700/1018.11082. Review.

PMID:
22322832
36.

Managing cardiac risk factors in oncology clinical trials.

Tsimberidou AM, Minotti G, Cardinale D.

Tex Heart Inst J. 2011;38(3):266-7. Review. No abstract available.

37.

Anthracycline cardiotoxicity.

Menna P, Paz OG, Chello M, Covino E, Salvatorelli E, Minotti G.

Expert Opin Drug Saf. 2012 May;11 Suppl 1:S21-36. doi: 10.1517/14740338.2011.589834. Epub 2011 Jun 2. Review.

PMID:
21635149
38.

Matters of the heart: the case of TNFalpha-targeting drugs.

Cacciapaglia F, Menna P, Navarini L, Afeltra A, Salvatorelli E, Minotti G.

Mol Interv. 2011 Apr;11(2):79-87. doi: 10.1124/mi.11.2.4. No abstract available.

PMID:
21540466
39.

Cardiovascular safety of anti-TNF-alpha therapies: facts and unsettled issues.

Cacciapaglia F, Navarini L, Menna P, Salvatorelli E, Minotti G, Afeltra A.

Autoimmun Rev. 2011 Aug;10(10):631-5. doi: 10.1016/j.autrev.2011.04.014. Epub 2011 Apr 22. Review.

PMID:
21539939
40.

Pharmacological foundations of cardio-oncology.

Minotti G, Salvatorelli E, Menna P.

J Pharmacol Exp Ther. 2010 Jul;334(1):2-8. doi: 10.1124/jpet.110.165860. Epub 2010 Mar 24.

41.

Iron regulatory proteins: from molecular mechanisms to drug development.

Recalcati S, Minotti G, Cairo G.

Antioxid Redox Signal. 2010 Nov 15;13(10):1593-616. doi: 10.1089/ars.2009.2983. Review.

PMID:
20214491
42.

Anthracycline degradation in cardiomyocytes: a journey to oxidative survival.

Menna P, Salvatorelli E, Minotti G.

Chem Res Toxicol. 2010 Jan;23(1):6-10. doi: 10.1021/tx9003424.

PMID:
19954191
43.

Report and recommendations of the workshop of the European Centre for the Validation of Alternative Methods for Drug-Induced Cardiotoxicity.

Stummann TC, Beilmann M, Duker G, Dumotier B, Fredriksson JM, Jones RL, Hasiwa M, Kang YJ, Mandenius CF, Meyer T, Minotti G, Valentin YJ, Zünkler BJ, Bremer S.

Cardiovasc Toxicol. 2009 Sep;9(3):107-25. doi: 10.1007/s12012-009-9045-3. Epub 2009 Jul 2.

PMID:
19572114
44.

4'-Epidoxorubicin to re-explore anthracycline degradation in cardiomyocytes.

Menna P, Salvatorelli E, Minotti G.

Chem Res Toxicol. 2009 Jun;22(6):978-83. doi: 10.1021/tx900039p.

PMID:
19397277
45.

Doxorubicinolone formation and efflux: a salvage pathway against epirubicin accumulation in human heart.

Salvatorelli E, Menna P, Lusini M, Covino E, Minotti G.

J Pharmacol Exp Ther. 2009 Apr;329(1):175-84. doi: 10.1124/jpet.108.149260. Epub 2009 Jan 14.

46.

Anthracycline cardiotoxicity: from bench to bedside.

Gianni L, Herman EH, Lipshultz SE, Minotti G, Sarvazyan N, Sawyer DB.

J Clin Oncol. 2008 Aug 1;26(22):3777-84. doi: 10.1200/JCO.2007.14.9401.

47.

Beyond poisons and problems: toxicology in Italy.

Preziosi P, Minotti G.

Chem Res Toxicol. 2008 Apr;21(4):771-4. doi: 10.1021/tx8000847. No abstract available.

PMID:
18422367
48.

Cardiotoxicity of antitumor drugs.

Menna P, Salvatorelli E, Minotti G.

Chem Res Toxicol. 2008 May;21(5):978-89. doi: 10.1021/tx800002r. Epub 2008 Apr 1.

PMID:
18376852
49.

Anthracycline cardiotoxicity.

Menna P, Salvatorelli E, Gianni L, Minotti G.

Top Curr Chem. 2008;283:21-44. doi: 10.1007/128_2007_11.

PMID:
23605627
50.

Sildenafil in older patients with secondary pulmonary hypertension.

Minotti GC, Corsonello A, Incalzi RA.

J Am Geriatr Soc. 2007 Oct;55(10):1681-2. No abstract available.

PMID:
17908072

Supplemental Content

Loading ...
Support Center